Fortress Biotech Pref Share FBIOP 9.375 15/12/22 | 8-K: FY2025 Q3 Revenue: USD 17.63 M

Revenue: As of FY2025 Q3, the actual value is USD 17.63 M.

EPS: As of FY2025 Q3, the actual value is USD 0.11.

EBIT: As of FY2025 Q3, the actual value is USD -4.805 M.

Segment Revenue

• Total net revenue increased by 20.5% to $17.6 million for the third quarter of 2025 compared to the third quarter of 2024.
• Journey Medical’s net product revenues for the third quarter ended September 30, 2025, were $17.0 million, compared to $14.6 million for the third quarter ended September 30, 2024.

Operational Metrics

• Consolidated net income attributable to common stockholders was $3.7 million, or $0.13 per share basic, and $0.11 per share diluted, for the third quarter ended September 30, 2025, compared to a net loss of - $15.0 million, or - $0.76 per share basic and diluted, for the third quarter ended September 30, 2024.
• Consolidated research and development expenses totaled $0.2 million for the third quarter ended September 30, 2025, compared to $9.4 million for the third quarter ended September 30, 2024.
• Consolidated selling, general and administrative costs were $17.4 million for the third quarter ended September 30, 2025, compared to $22.0 million for the third quarter ended September 30, 2024.

Cash Flow

• As of September 30, 2025, Fortress’ consolidated cash and cash equivalents totaled $86.2 million, compared to $57.3 million as of December 31, 2024, an increase of $28.9 million year-to-date.

Unique Metrics

• Fortress received approximately $28 million upfront from the acquisition of Checkpoint by Sun Pharma, with the potential for an additional CVR payment of up to $4.8 million and a 2.5% royalty on future net sales of UNLOXCYT (cosibelimab-ipdl).

Outlook / Guidance

• Fortress anticipates the resubmission of the New Drug Application for CUTX-101, which may qualify for a Priority Review Voucher upon approval.
• The company remains focused on disciplined execution, optimizing capital allocation, and advancing high-impact assets to drive sustainable growth and deliver innovative treatments to patients worldwide.